A novel multimodal nanoparticle, simultaneous multiple aptamers and RGD targeting, which combines triple affinity for nucleolin, RGD-containing integrins, and TNC, has been reported as a candidate for a targeted therapy against TNC (126): the nanoparticle would be well worth trying in SAH and other stroke types, considering the possible effects on both RGD-dependent integrins and TNC. Here, TNC is linked to Stroke.